Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E.coli autovaccine
- Development stage
- Unknown
- Lead developer
- Institute Torlak
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous, Oral
01
Overview
E.coli autovaccine is an individually prepared, patient-specific vaccine made from inactivated strains of Escherichia coli isolated from the patient’s own infection site. It is used as a therapeutic and preventive measure for persistent or recurrent infections caused by multidrug-resistant or antibiotic-refractory E. coli, particularly in cases such as urinary tract infections (UTIs), chronic prostatitis, and other chronic bacterial infections of the urogenital system, respiratory tract, skin/wounds, and ENT regions[1][2][6][8]. The mechanism involves stimulating the patient's immune system to recognize and mount a targeted response against their specific infecting strain(s) of E. coli by presenting antigens derived from those bacteria[1][2][6]. This approach can reduce recurrence rates of infection and decrease reliance on antibiotics[2]. Autovaccines are typically administered sublingually (as drops) or intramuscularly depending on clinical context[1][2][6].
- Other names
- Escherichia coli autogenous vaccineE. coli autovaccineE. coli autogenous vaccine
02
Targets
Patient-specific Escherichia coli antigens
Beyond the preview
Go deeper on E.coli autovaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E.coli autovaccine.